Today’s Understanding of MPNs: Article Reviews in ASH Journal Blood The world’s current understanding of myeloproliferative neoplasms (MPNs) is showcased in a review of MPN articles

An Important Time for MPNs “This is a profoundly important moment in the treatment of MPNs,” according to Raajit Rampal, MD, PhD, a hematology/oncology specialist

MPNRF ADVANCING RESEARCH: Nanobody-Based Targeted Therapy Through a 2022 MPNRF Thrive Initiative award, Najla Arshad, PhD, Yale University School of Medicine, will explore Development of

MPN Research Foundation Awards Additional $1.8 Million for Blood Cancer Research into Myeloproliferative Neoplasms Dec. 14, 2022 (Chicago) − MPN Research Foundation (MPNRF) announces its

Before he helped define criteria for the diagnosis of polycythemia vera (PV) and introduced interferon to treat it; before he chaired the guidelines committee for

Our investments in global, cutting edge, multi-center MPN research have directly advanced knowledge about the causes of these rare, chronic blood cancers, leading to the